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Abstract: We report the case of a boy with an encephalopathy associated 
with extrapyramidal and psychiatric symptoms and anti-N-methyl-D-aspar-
tate receptor antibodies. He had positive serum antithyroid antibodies, IgM 
antibodies against Mycoplasma pneumoniae and human herpesvirus 7 poly-
merase chain reaction in the cerebrospinal fluid. He was successfully treated 
with rituximab, after steroids, intravenous immunoglobulin and plasma 
exchange. The pathophysiology of this disorder may be post-infectious and 
autoimmune.  
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Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune encephalitis first characterized by Dalmau et 
al1 in 2007. The disorder affects predominantly children and young 
adult women.2 It is associated with a tumor in 42% of the patients, 
but the precise pathological background remains elusive.2
Clinical features are psychiatric symptoms, disturbance of con-
sciousness, generalized seizures, abnormal involuntary movements, 
autonomic dysfunction and central hypoventilation.2,3 The diagnosis is 
based on the clinical course and, in addition, on the demonstration of 
anti-NMDAR antibodies in the serum and cerebrospinal fluid (CSF).
In patients with a tumor, predominantly an ovarian tera-
toma, the condition is treated by tumor removal, whereas first-line 
immunotherapy [corticosteroids plus intravenous immunoglobulin 
(IVIg) or plasma exchange] has been proposed in previous reports.2 
When no response is seen second-line immunotherapy (rituximab 
and/or cyclophosphamide) should be considered.4–6
The pathogenesis of anti-NMDAR encephalitis is unclear. 
Although recent studies showed that a few patients with non-tumor-
associated anti-NMDAR encephalitis have elevated antithyroid 
peroxidase (anti-TPO) antibodies,5–7 the combined occurrence of 
anti-NMDAR and anti-TPO antibodies was not followed up in 
detail in the literature.
Neurologic disease associated with Mycoplasma pneumonia 
and Human herpesvirus 7 (HHV-7) infections have been described 
rarely contrasting with the occurrence of nearly universal primary 
infection in early childhood.8
We report an anti-NMDAR encephalitis in a 9-year-old boy, 
not associated with malignancy, with positive serum antithyroid 
antibodies, IgM antibodies against Mycoplasma pneumoniae and 
HHV-7 polymerase chain reaction (PCR) in the CSF that showed 
significant improvement after administration of rituximab.
CASE PRESENTATION
A 9-year-old boy initially had upper respiratory symptoms 
and low-grade fever. One week later, he progressively developed 
limb muscle weakness, fatigue, waddling gait, refusal to walk, 
changes of mood and self-injurious behavior. He was seen at a local 
hospital with a severe headache and vomiting. CT-scan was normal 
and the symptoms improved. Two weeks later, he manifested inco-
herent delirious and obsessive thoughts, slurred speech and a mild 
motor incoordination. He was fully awake, with periods of agitation. 
Neurologic examination did not indicate any other abnormalities. 
Extensive investigations for metabolic, infectious, toxic, autoim-
mune and central nervous system disorders were performed. CSF 
cyto and biochemical analyses were normal. Brain magnetic reso-
nance imaging fluid-attenuated inversion recovery showed bilateral 
medial temporal lobe hyperintensities, predominantly involving the 
left hippocampus. Electroencephalogram demonstrated right-sided, 
fronto-temporal slowing without epileptiform discharges. Consid-
ering encephalitis, he was treated with acyclovir, ceftriaxone and 
ciprofloxacin.
Further CSF analysis showed elevated IgG and IgM indexes, 
oligoclonal bands and a pattern of increased permeability of the 
blood-brain barrier. CSF culture was negative for bacteria. PCR-
based analysis of CSF and enzyme-linked immunosorbent assays 
antibody titers in serum and CSF samples were suggestive of Myco-
plasma infection with positive IgM in serum (negative antibodies 
and PCR in CSF); it also revealed a positive PCR for HHV-7 (in 2 
consecutive samples). He completed a 21 day course of ceftriaxone 
and ciprofloxacin. After acyclovir, he completed a 10 day course of 
foscarnet. HHV-7 CSF PCR became negative after this treatment.
Serum anti-thyroglobulin (TG-138 U/mL, normal range 
0~60 U/mL) and anti-TPO (>1300 U/mL, normal range 0–60 U/mL) 
antibodies were markedly elevated, with normal thyroid stimulating 
hormone and mildly diminished free T3 (2.1 pg/mL).
During the first week after admission, the patient’s condition 
deteriorated progressively: psychiatric symptoms worsened (severe 
agitation, auditory hallucinations, delusions, crying out and perse-
veration), he developed a sleep disorder (hypersomnia and insomnia) 
and speech production diminished to a state of mutism. Intense oro-
facial dyskinesia, sometimes associated with lip-biting and choreic 
movements in the left upper limb supervened. He also had autonomic 
dysfunction (constipation, mild tachycardia, hypertension, apnea and 
hyperventilation). Electroencephalogram on day 2 revealed a back-
ground of generalized slow and disorganized activity, but also inter-
mittent low voltage beta that was phase locked to underlying delta 
activity. Risperidone and imipramine were added to treatment at this 
time. Because the patient’s condition did not improve, he was sub-
sequently treated with methylprednisolone (30 mg/kg/d for 3 days/2 
cycles), IVIg (1 g/kg/d for 2 days) and plasma exchange (5 times/2 
cycles and 3 weekly sessions), with minor improvement.
The clinical profile was suggestive of anti-NMDAR enceph-
alitis: serum and CSF anti-NMDAR antibodies collected on day 5 
(Molecular Biology Laboratory, Oxford Hospital), before immu-
notherapy and plasma exchange had been initiated, were highly 
positive. Whole-body PET scan revealed no indication of a tumor 
lesion. We started, on the 51st day in hospital, weekly rituximab, a 
monoclonal anti-CD20 antibody, 375 mg/m2/wk, approved by the 
hospital´s Ethics Committee, for a total of 4 doses. One isolated 
anaphylaxis episode was associated with the first dose of rituximab; 
this resolved promptly with adrenaline.
Clinical symptoms, including the disturbance of conscious-
ness, psychiatric symptoms, involuntary movements and auto-
nomic dysfunction markedly improved 1 week after the first admin-
istration. In parallel, abnormal findings on electroencephalogram 
progressively normalized. On day 65, the patient was discharged, 
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Abstract: Drug resistance in children with tuberculosis is usually primary 
(transmitted); however, resistance acquisition during treatment is possi-
ble. We describe a child with tuberculosis who acquired drug resistance 
while receiving directly observed but inadequate first-line therapy and the 
programmatic and clinical factors that may have contributed to resistance 
acquisition. 
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with only mild self-injurious behavior when facing frustrating situ-
ations and coprolalia.
Progressive improvement of cognitive and motor neurologi-
cal functions took place over the next 6 months, returning to school 
with a good recovery. He was able to return to school and resumed 
all his previous activities. Testing for anti-TG and anti-NMDAR 
antibodies was negative 6 months after diagnosis. Serum anti-TPO 
antibodies titers persisted elevated.
DISCuSSION
Our case had a classic clinical picture of anti-NMDAR 
encephalitis resulting from the loss of NR1 subunit of NMDA 
receptors as presented in the current literature, including psy-
chotic behavior, dysfunction of dopaminergic pathways (orofacial 
dyskinesia) and dysautonomia (cardiac dysrhythmia and central 
hypoventilation).2
M.pneumoniae serology was positive, but CSF antibody 
tests and PCR were negative, as reported by others. The signifi-
cance of this finding is unclear given the high prevalence of posi-
tive serologies in most series of pediatric encephalitis.2,3 However, 
M. pneumoniae infection can result in the development of autoan-
tibodies against neuronal membrane and this biological mimet-
ism can be associated with central nervous system immunologic 
events.3 Despite the high sensitivity of enzyme-linked immuno-
sorbent assays, relying on a single serological test can be clinically 
misleading. Moreover, plasmapheresis made it impossible to base 
the diagnosis of acute infection on seroconversion measured simul-
taneously in assays for both IgM and IgG, as recommended.
HHV-7 can produce encephalopathy in children but many 
cases in which HHV-7 is detected in the CSF have an alternative 
etiology for their illness, as latent DNA integrated or reactivated 
virus may not be causally related to disease. In our case, however, 
CSF PCR became negative after treatment with foscarnet and this 
may be relevant.8 HHV-7 has been described in association with 
influenza-associated encephalopathy, but the authors have not 
found any reported case stating this evidence.8 Recent observations 
suggest that herpesviruses may have a unique role in promoting 
development of autoimmune antibodies, as patients with herpes 
simplex 1 encephalitis developed anti-NMDAR encephalitis weeks 
or months after acute episode.9
Anti-NMDAR encephalitis is not always a paraneoplastic 
disorder; a post-infectious autoimmune process may also be impli-
cated in etiology, reinforcing the possible relevance of Mycoplasma 
and HHV-7.2
In patients without a tumor, first-line immunotherapy, using 
corticosteroids, IVIg, plasma exchange may not be effective, thus 
second-line immunotherapy (eg, rituximab and/or cyclophospha-
mide) is usually needed.3,4 Globally, nearly 75% of the patients 
make a good recovery after tumor removal and/or immune-mod-
ulatory treatments, although the time to full recovery is variable 
(1–14 months), with a median of 2.5 months.2 Our patient fully 
recovered in 6 months.
Importantly, serial NMDAR antibodies levels seem to cor-
relate with clinical severity. Rituximab causes a decrease in B cells, 
prevents maturation into antibody-secreting cells and suppresses 
B cell function more selectively and continuously than first-line 
immunotherapy.10 In addition, it causes a form of immune system 
resetting because of the depletion of memory B cells and prevents 
them from stimulating T lymphocytes. Therefore, rituximab seems 
effective for treatment of anti-NMDAR encephalitis resistant to 
first-line immunotherapy.10 An infusion related reaction, tachycar-
dia and anaphylaxis, was seen in our case but resolved promptly, 
without further serious adverse effects. The available evidence 
that rituximab is effective for this type of encephalitis enhances 
our understanding of the disease. It is unclear whether its early use 
to control the immune response within the central nervous system 
would shorten the duration of symptoms. Thus, considering the B 
cell-selective pharmacological effects and the limited side effects 
of rituximab, this treatment may be particularly useful in young 
anti-NMDAR encephalitis patients without tumor lesions.2,4
Unlike 2 recently reported patients with anti-NMDAR 
encephalitis cases with anti-TPO and infectious serology concur-
rence,11 our patient had a complete clinical recovery both on dis-
charge and 6 months later. Persistent high titers of serum anti-TPO 
antibodies not only suggest a propensity to autoimmunity in cases 
of anti-NMDAR encephalitis, but also support the notion that neu-
ronal and thyroid autoimmunities may be part of a pathogenic spec-
trum. More detailed clinical analysis is necessary to elucidate the 
etiology of anti-NMDAR encephalitis.
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